Sanofi seeks to oust Medivation board

Aggressive action comes after US drugs group rejects $9.3bn offer

FDA delays Sarepta dystrophy drug ruling

Biotech company’s shares jump on hopes medicine could be approved

Medicines regulator warns of Brexit hit

Watchdog would struggle with more work and less income, says chief

Stacie Al-Chokhachi and her son, Dalton, 11, who suffers from Duchenne muscular dystrophy, with hundreds of other Duchenne patients and family members at a Food and Drug Administration meeting about whether a new drug for for treatment of the disease should be approved, in Hyattsville, Md., April 25, 2016. The drug's manufacturer and patient advocates argued that it was clear from even a small study that the drug, called eteplirsen, was prolonging the ability of boys with the disease to walk well beyond when they would typically be in wheelchairs. (Eric Kruszewski/The New York Times) Credit: New York Times / Redux / eyevine For further information please contact eyevine tel: +44 (0) 20 8709 8709 e-mail: info@eyevine.com www.eyevine.com

US healthcare: Power to the patients?

Families of boys suffering from Duchenne muscular dystrophy push for approval of a new medicine

World Bank launches pandemic finance facility

G7 finance ministers announce $500m emerging diseases fund

Bayer’s Monsanto bid raises funding fears

Concerns grow about deal cost and impact on credit rating

Monsanto bid is bold move for Bayer chief

Share price fall highlights scale of Werner Baumann’s gamble

Unite to prevent a superbug apocalypse

Drug companies need market incentives to generate new antibiotics

Big pharma slams tax to tackle superbugs

Drugmakers reject levy to fund R&D on antimicrobial resistance

©FT Montage/Reuters

Pharma levy proposed in superbugs battle

UK eyes ‘play or pay’ scheme in search for effective antibiotics

Snake antivenom boost adds bite to BTG

Data strengthen case for wider use of group’s second-biggest product

AstraZeneca gets asthma drug trial boost

UK pharma group on track to file injectable treatment with regulators

Pfizer buys Anacor for $5.2bn

Pharma group in deal for new products ahead of potential break-up

Biotech sinks its teeth into the Big Apple

New York’s budding hub reaches tricky point in its development

A tale of two healthcare systems

For patients in the US and the UK, managing a chronic disease poses very different problems

Regulators under pressure on drug quality

Asia is producing a growing share of Europe’s medicines

Soaring US drug prices spark debate

America is responsible for a third of global drug spending

Drug regulators strengthen transatlantic collaboration

Speeding the path for new drugs offers rewards for patients and industry

Pfizer blocks its drugs from use in executions

Drugmaker restricts products used in lethal injection

Bayer explores $40bn bid for Monsanto

Latest sign of consolidation in agrochemicals

EDITOR’S CHOICE

Special report

insulin vials ©Jacob Ehrbahn Combating Diabetes

Special report

An elderly man uses a magnifier to see the descriptions on a pack of medicine at a pharmacy in Dandong, Liaoning province March 30, 2011 ©Jacky Chen/Reuter Health: Emerging Markets

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE